BioMarin Pharmaceutical has commenced a Phase III study of pegylated recombinant phenylalanine ammonia lyase (PEG-PAL) for the treatment of phenylketonuria (PKU), a genetic disorder.

Around 90 treatment-naïve adult PKU subjects will self-administer PEG-PAL as part of the open-label, multi-centre study, which is designed to assess the drug’s safety and tolerability during induction, titration and maintenance dosing.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The study’s secondary objective is to assess blood Phe levels.

BioMarin chief medical officer Dr Hank Fuchs said the previous Phase II trial demonstrated a dramatic reduction in blood Phe levels due to PEG-PAL, and a similar outcome is expected of the Phase III programme.

“Around 90 treatment-naïve adult PKU subjects will self-administer PEG-PAL as part of the open-label, multi-centre study, which is designed to assess the drug’s safety and tolerability during induction, titration and maintenance dosing.”

“Adult patients with PKU and patients on the severe end of the disease spectrum still represent a very high unmet medical need,” Fuchs said.

“With PEG-PAL, it may be possible to provide a treatment benefit to this population.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

On completion of study, the subjects are expected to be enrolled in a second Phase III study, along with 60 subjects currently being treated with PEG-PAL in the Phase II programme.

Designed to determine the efficacy and safety of PEG-PAL in self-administered by PKU adults, the primary objective of this second Phase III double-blind, placebo-controlled study will be to evaluate blood Phe levels.

The secondary objective will be to evaluate changes in neuropsychiatric assessments as measured by the Inattentive portion of the Attention Deficit and Hyperactivity Disorder Rating Scale and the Profile of Mood States.